Novacyt (ALNOV) H2 2024 earnings summary

Executive summary

• Completed major consolidation, merging two businesses into a Manchester-based center of excellence, reducing operational complexity and cost base.

• Achieved significant cost synergies and operational savings, with £8m delivered ahead of schedule and £5m from the Yourgene acquisition.

• Strengthened leadership team and board, with new CEO, CFO, CSO, and Chairman appointments.

• Focused on IVDR certification, securing approvals for key reproductive health and precision medicine products.

• FY2024 marked a transition year with the integration of Yourgene, site consolidations, and portfolio rationalization.

Financial highlights

• Group revenue rose 85% year-over-year to £19.6m, driven by the Yourgene acquisition and strong growth in reproductive health (26%) and Ranger consumables (13%).

• Gross profit reported at £32.1m (163% margin), inflated by a £19.8m one-time provision reversal; underlying gross profit £12.3m (63% margin).

• EBITDA loss reduced to £9.1m (improved from £11.8m loss in FY2023).

• Loss after tax of just under £42m, impacted by exceptional items and impairments.

• Year-end cash position at £30.5m, with Q1 2025 cash at £28m.

Outlook and guidance

• Q1 2025 trading in line or slightly above expectations for revenue and EBITDA; four new product launches planned for 2025.

• On track to deliver further cost savings and bottom-line improvements through site closures and operational efficiencies.

• Over £2m to be reinvested in R&D to drive organic growth and new product launches in H2 2025.

• Confident in sufficient cash reserves to self-fund through to profitability.

• Comprehensive growth strategy and new product details to be shared by end of summer/H2 2025.